Elsevier

Maturitas

Volume 24, Issue 3, July 1996, Pages 177-184
Maturitas

A comparison of the effects of oral conjugated equine estrogen and transdermal estradiol-17β combined with an oral progestin on quality of life in postmenopausal women

https://doi.org/10.1016/S0378-5122(96)82007-XGet rights and content

Abstract

Objective: To compare the effect of transdermal estradiol-17β and oral conjugated equine estrogen when combined with an oral progestin on quality of life in post-menopausal women. Design: Randomized controlled double-blind trial. A randomization error lead to the exclusion of six subjects but the soundness of the remaining randomization was confirmed. Setting: Large urban community. Patients: Women 2–7 years after menopause with a uterus and ovaries, and not currently using hormone replacement therapy. Seventy-four women completed the trial. Interventions: After baseline measures of quality of life, subjects were randomly assigned to either continuous oral conjugated equine estrogen 0.625 mg daily or continuous transdermal estradiol-17β 50 mcg twice weekly, for four 4-week cycles. Medroxyprogesterone acetate 10 mg oral tablets was administered to both groups for the last 12 days of each cycle.

Outcomes measured: Quality of life was determined using the Menopause-Specific Quality of Life Questionnaire. Tolerability was determined by a specifically designed list of adverse effects. Both measures were recorded at base-line and in mid-cycle during the second, third and fourth cycles of treatment.

Results: There were no statistically significant differences in any of the domains at baseline between the oral and transdermal treatment groups. In the vasomotor domain, scores for the oral and transdermal groups improved from baseline levels of 3.14 and 3.09, respectively, to 1.32 and 1.23; physical domain scores improved from 2.45 and 2.73 to 2.04 and 1.78; psychosocial domain scores improved from 2.72 and 3.04 to 2.21 and 1.94; sexual domain scores improved from 2.32 and 2.16 to 1.64 and 1.30. There were no statistically significant group differences or time/group interactions. Both forms of therapy were equally well tolerated.

Conclusions: Improvement in all domains, measured by the Menopause-Specific Quality of Life Questionnaire, was observed in both the oral and transdermal groups. In the absence of a placebo control group, the improvements observed cannot be attributed solely to the therapy. Neither form of therapy offered an advantage over the other in respect to improvement in quality of life.

References (25)

  • Y Erlik et al.

    Association of waking episodes with menopausal hot flashes

    JAMA

    (1981)
  • I Schiff et al.

    Effects of estrogen on sleep and psychological states of hypogonadal women

    JAMA

    (1979)
  • Cited by (70)

    • Quality of life of patients with bilateral oophorectomy before the age of 45 for the treatment of endometriosis

      2022, Maturitas
      Citation Excerpt :

      This could be considered as surprising since more than 71% of the women indicated still experiencing hot flushes although there was no significant difference in the mean vasomotor domain score between current HRT users and non-users. This is in contrast to the results of most studies, which reported an improvement in every domain of the MenQOL questionnaire in postmenopausal women who were treated with menopause hormone therapy [41–45]. It is more likely that there is a lack of power in our study since there was a clear trend towards worser scores in the vasomotor domain in untreated women compared to current users.

    • The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation

      2011, Gynecologic Oncology
      Citation Excerpt :

      The majority of women who were premenopausal at the time of surgery had a significant worsening of vasomotor symptoms after surgery (hot flashes, night sweats and sweating) (p < 0.0001) and a decline in sexual functioning (decrease in sexual desire, vaginal dryness, and avoidance of intimacy) (p < 0.0001). Compared to published norms [20,26], women who were premenopausal at the time of surgery decreased in these domains to levels similar to women who are two to seven years post-menopause (see Table 3). Women who were taking HRT had significantly fewer vasomotor symptoms (p = 0.0003) and reported better sexual functioning (p = 0.015) after surgery than women who were not taking HRT.

    • Issues Relating to Quality of Life in Postmenopausal Women and Their Measurement

      2007, Treatment of the Postmenopausal Woman: Basic and Clinical Aspects, Third Edition
    View all citing articles on Scopus
    View full text